Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 212

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 212
---
 in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.

Withholding under FATCA currently applies to dividends paid in respect of our common shares. Proposed Treasury Regulations, the preamble to which state that they can be relied upon until final Treasury Regulations are issued, exempt from FATCA withholding gross proceeds from the dispositions of stock. To prevent withholding on dividends, Non-U.S. Holders may be required to provide the Company (or its withholding agents) with applicable tax forms or other information. Non-U.S. Holders are urged to consult with their own tax advisors regarding the effect, if any, of FATCA to them based on their particular circumstances.

<div align='center'>147

SELLING SHAREHOLDER</div>

This prospectus relates to the offer and sale from time to time by the Selling Shareholder of up to 2,680,000 common shares issuable upon the exercise from time to time of the Private Warrants by the Selling Shareholder. We are registering the common shares being offered by this prospectus pursuant to the provisions of the Warrant Inducement Agreement we entered into with the Selling Shareholder on July 14, 2025. The participation of the Selling Shareholder in the filing of this prospectus is not an indication of such Selling Shareholder's intention to sell its common shares at any particular time or in any particular amount, or at all.

As used in this prospectus, the term "Selling Shareholder" means Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, and the pledgees, donees, transferees, assignees, successors, designees, and others who later come to hold any of the Selling Shareholder's interest in the common shares other than through a public sale.

The table below presents information regarding the Selling Shareholder and the common shares under this prospectus. This table is prepared based on information supplied to us by the Selling Shareholder and reflects holdings as of November 7, 2025. The number of common shares in the column entitled "Maximum Number of Common Shares Being Offered" represents all of the common shares being offered for sale by the Selling Shareholder under this prospectus. The Selling Shareholder may sell some, all, or none of the shares being offered for sale in this offering. We do not know how long the Selling Shareholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling Shareholder and any other